Stock CGON CG ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus CG Oncology, Inc.

Equities

CGON

US1569441009

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
29.98 USD -3.20% Intraday chart for CG Oncology, Inc. +5.19% 0.00%
May. 14 Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target MT
May. 09 CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on CG Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

aed6d8.RVziz0uIlOdYDbISd8rx18slBPo8YL1KHlTmH6BQGzw.By-wuA7JzJ0NOIB9GbPCgYlIW6NNVfo5Rgaka9RjY180ErGoM8TBpC1Vhg~e0eecff7fb9b67e2f61ca19b48dcd7c5

Analyst Recommendations on CG Oncology, Inc.

Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target MT
Cantor Fitzgerald Starts Coverage on CG Oncology With Overweight Rating, $75 Price Target MT
Goldman Sachs Initiates Coverage on CG Oncology With Neutral Rating, $42 Price Target MT
Morgan Stanley Initiates CG Oncology With Overweight Rating, Price Target is $55 MT
HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
29.98 USD
Average target price
68.2 USD
Spread / Average Target
+127.48%
High Price Target
86 USD
Spread / Highest target
+186.86%
Low Price Target
50 USD
Spread / Lowest Target
+66.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering CG Oncology, Inc.

Goldman Sachs
Cantor Fitzgerald
Morgan Stanley
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CGON Stock
  4. Consensus CG Oncology, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW